Loading clinical trials...
Loading clinical trials...
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Reference Study ID Number: ML45172 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. and Canada)[email protected]Lead Sponsor
Hoffmann-La Roche
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT03223610 · Lymphoma, Non-Hodgkin Lymphoma, and more
NCT03418038 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, and more
NCT05272384 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, and more
NCT07409428 · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Cancer Hospital Chinese Academy of Medical Sciences.
Langfang, Hebei
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
Tianjin, Tianjin Municipality
Peking University People's Hospital
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions